Alkermes plc. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
Alkermes plc. (ALKS) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of $522.00 thousand for the 12-month period ending 2013-03-31, per its 10-K filed 2015-02-24.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2015-02-24
- Alkermes plc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2013-03-31 was $0.00.
- Alkermes plc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2012-12-31 was $0.00.
- Alkermes plc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2012-09-30 was $594.00K.
- Alkermes plc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2012-06-30 was -$72.00K.
- Alkermes plc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2013 was $522.00K.
- Alkermes plc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2012 was -$327.00K.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 12 month |
|---|---|---|---|---|
| 2013-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $0.00 derived: sum of 2 quarters · filed 2015-02-24 | $594.00K derived: sum of 3 quarters · filed 2015-02-24 | $522.00K 10-K · filed 2015-02-24 |
| 2012-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $594.00K derived: sum of 2 quarters · filed 2013-10-31 | $522.00K 10-Q · filed 2013-01-31 | $471.00K derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-09-30 | $594.00K 10-Q · filed 2013-10-31 | $522.00K 10-Q · filed 2013-10-31 | $471.00K derived: sum of 3 quarters · filed 2014-02-27 | $438.00K derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | -$72.00K 10-Q · filed 2013-07-25 | -$123.00K derived: sum of 2 quarters · filed 2014-02-27 | -$156.00K derived: sum of 3 quarters · filed 2014-02-27 | -$400.00K derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | -$51.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | -$84.00K derived: sum of 2 quarters · filed 2014-02-27 | -$328.00K derived: sum of 3 quarters · filed 2014-02-27 | -$327.00K 10-KT · filed 2014-02-27 |
| 2011-12-31 | -$33.00K 10-Q · filed 2013-01-31 | -$277.00K derived: sum of 2 quarters · filed 2013-01-31 | -$276.00K 10-Q · filed 2013-01-31 | |
| 2011-09-30 | -$244.00K 10-Q · filed 2012-11-01 | -$244.00K 10-Q · filed 2012-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |